These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37088366)

  • 1. The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice.
    Varisco TJ; Wanat M; Hill LG; Thornton D
    J Am Pharm Assoc (2003); 2023; 63(4):1039-1043. PubMed ID: 37088366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.
    Ostrach B; Hill L; Carpenter D; Pollini R
    J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L; Ventricelli D; Aronowitz SV
    Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.
    Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M
    J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.
    Andrilla CHA; Patterson DG
    J Rural Health; 2022 Jan; 38(1):87-92. PubMed ID: 33733547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing buprenorphine supply barriers: A guidance commentary.
    Khail JW; Rawal S; Young HN; Caballero J
    J Am Pharm Assoc (2003); 2024; 64(2):377-379. PubMed ID: 38272311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX.
    Potter JS; Finley EP; King VL; Lanham HJ; Schmidt S; Schneegans S; Rosen KD
    J Subst Abuse Treat; 2022 Jun; 137():108688. PubMed ID: 35058105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act.
    Adams JA; Chopski NL; Adams AJ
    J Am Pharm Assoc (2003); 2023; 63(5):1495-1499. PubMed ID: 37295494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.
    Lanham HJ; Papac J; Olmos DI; Heydemann EL; Simonetti N; Schmidt S; Potter JS
    JAMA Netw Open; 2022 May; 5(5):e2212419. PubMed ID: 35552721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.
    Jarrett JB; Bratberg J; Burns AL; Cochran G; DiPaula BA; Legreid Dopp A; Elmes A; Green TC; Hill LG; Homsted F; Hsia SL; Matthews ML; Ghitza UE; Wu LT; Bart G
    Subst Abus; 2023 Oct; 44(4):264-276. PubMed ID: 37902032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy.
    Varisco TJ; Fish H; Bolin J; Dadiomov D; Hill LG; Essien EJ; Wanat MA; Ginsburg D; Waggener J; Yazdanfard S; Song J; Chi W; Thornton D
    Arch Public Health; 2024 Apr; 82(1):58. PubMed ID: 38664777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
    Hill LG; Light AE; Green TC; Burns AL; Sanaty Zadeh P; Freeman PR
    J Am Pharm Assoc (2003); 2023; 63(1):252-260.e6. PubMed ID: 36202711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.
    Auty SG; Stein MD; Walley AY; Drainoni ML
    J Subst Abuse Treat; 2020 Aug; 115():108032. PubMed ID: 32600629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.